Prelude Therapeutics (PRLD) Research & Development (2019 - 2026)

Prelude Therapeutics (PRLD) has 8 years of Research & Development data on file, last reported at $13.6 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 52.8% year-over-year to $13.6 million; the trailing twelve-month figure through Mar 2026 stood at $79.1 million (down 33.77% YoY), and the FY2025 full-year result was $94.3 million, down 20.08% from the prior year.
• Research & Development slipped to $13.6 million in Q1 2026, from $18.0 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $31.6 million in Q4 2024 to a low of $13.6 million in Q1 2026.
• A 5-year average of $24.8 million and a median of $25.8 million in 2025 frame the typical range for Research & Development.
• Across the five-year window, Research & Development soared 38.56% in 2022 and slumped 52.8% in 2026, its largest moves.
• Tracing PRLD's Research & Development over 5 years: stood at $25.9 million in 2022, then gained by 17.25% to $30.3 million in 2023, then grew by 4.25% to $31.6 million in 2024, then plunged by 43.1% to $18.0 million in 2025, then decreased by 24.41% to $13.6 million in 2026.
• Business Quant data shows PRLD's Research & Development at $13.6 million in Q1 2026, $18.0 million in Q4 2025, and $21.7 million in Q3 2025.